Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology, St.Petersburg 197758, Russia.
Ann Transl Med. 2014 Jun;2(6):60. doi: 10.3978/j.issn.2305-5839.2014.06.02.
Evidence has emerged that antidiabetic biguanides [phenformin (PF), buformin (BF) and metformin (MF)] are promising candidates for prevention of cancer. It was shown that antidiabetic biguanides postpone spontaneous carcinogenesis as well as inhibit carcinogenesis induced by chemical, radiation and biological factors (virus, transgene, genetic modifications, special diet, etc.) in a number of organs and tissues in various strains of mice and rats. The present review focused on some details of experiments such as design of studies, dose and route of administration of biguanide, and age of animals at start of treatment etc. Conclusion may be done that there are rather sufficient evidence of cancer-preventive activity of antidiabetic biguanides in experimental animals.
有证据表明，抗糖尿病双胍类药物[苯乙双胍（PF）、丁双胍（BF）和二甲双胍（MF）]是预防癌症的有前途的候选药物。研究表明，抗糖尿病双胍类药物可延缓自发性癌变，并抑制化学、辐射和生物因素（病毒、转基因、基因修饰、特殊饮食等）在多种器官和组织中的致癌作用，在不同品系的小鼠和大鼠中。本综述重点介绍了一些实验细节，如研究设计、双胍类药物的剂量和给药途径以及治疗开始时动物的年龄等。结论可以得出，在实验动物中，抗糖尿病双胍类药物具有相当充分的抗癌活性证据。
